APGE NASDAQ
Apogee Therapeutics, Inc.
1W: -5.6%
1M: -13.9%
3M: +11.4%
YTD: +3.3%
1Y: +92.7%
$80.12
+1.85 (+2.37%)
Weekly Expected Move ±4.7%
$74
$77
$81
$85
$89
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$4.8B
52W Range34.34-95.315
Volume765,264
Avg Volume884,777
Beta0.69
Dividend—
Analyst Ratings
Company Info
CEOMichael Thomas Henderson
Employees196
SectorHealthcare
IndustryBiotechnology
IPO Date2023-07-14
Websiteapogeetherapeutics.com
221 Crescent Street
Waltham, MA 02453
US
Waltham, MA 02453
US
650-394-5230
About Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
Latest News
Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results
Aberdeen Group plc Lowers Stake in Apogee Therapeutics Inc. $APGE
Banque Pictet & Cie SA Invests $3.16 Million in Apogee Therapeutics Inc. $APGE
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $403 Million
Apogee CEO Sells 20,000 Shares as Stock Surges Nearly 100% in a Year, but Here's What Really Matters for Investors
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| HENDERSON MICHAEL TH | S-Sale | 18,659 | $82.05 | 2026-05-13 |
| HENDERSON MICHAEL TH | S-Sale | 1,341 | $82.58 | 2026-05-13 |
| Dambkowski Carl | M-Exempt | 4,125 | $22.86 | 2026-05-06 |
| Dambkowski Carl | S-Sale | 3,700 | $83.92 | 2026-05-06 |
| Dambkowski Carl | S-Sale | 1,800 | $84.60 | 2026-05-06 |